SELLAS Life Sciences Group (SLS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.04
- Surprise
- —
- Score today
- 5.0/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- 10 Health Care Stocks With Whale Alerts In Today’s Session — benzinga, 2026-08-12
- SELLAS Life Sciences Gr Q2 EPS $(0.05) Misses $(0.04) Estimate — benzinga, 2026-08-11
Where TrendMatrix's rating stands now
TrendMatrix currently rates SLS Sell at 5.0/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-11.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $32.50 vs price $10.38 — ratio 3.1×). Rejected, falling back to technical TP.
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $10.38
- Price target
- $12.45
- Stop
- $9.65
- Upside to target
- +19.9%
Risk check: trading volume is running 3.6× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
SLS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.10B
- P/E (fwd)
- -103.8
- 52-week range
- $1.39–$15.88
- Off 52-week high
- 34.6%
- RSI (14)
- 45
- Volume vs avg
- 3.65×
- Score today
- 5.0/10